(Q36066191)

12 August 2017

1 reference

title

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway (English)

1 reference

12 August 2017

Herbert B Newton

1

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

177-191

1 reference

Current epidemiological trends and surveillance issues in brain tumors

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Chemotherapy for the treatment of metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Tumor suppressor genes and cancer of the human nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular pathways in the formation of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The role of p53 in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The emerging p53 gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The p53 protein is an unusually shaped tetramer that binds directly to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Regulation of p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Molecular mechanism of the interaction between MDM2 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The ubiquitin ligase COP1 is a critical negative regulator of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Definition of a consensus binding site for p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

GADD45 induction of a G2/M cell cycle checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

A novel form of Epstein-Barr virus latency in normal B cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Germline p53 gene mutations in subsets of glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Subsets of glioblastoma multiforme defined by molecular genetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Therapeutic exploitation of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Reactivation of mutant p53: a new strategy for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Apoptosis, cancer and the p53 tumour suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Genetically modified adenoviruses against gliomas: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The INK4a/ARF network in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Discovering novel chemotherapeutic drugs for the third millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

The impact of genomic and proteomic technologies on the development of new cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Microarrays as cancer keys: an array of possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Application of microarrays to neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

Checkpoints: How to activate p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.177

21 January 2018

Identifiers

DOI

10.1586/14737140.5.1.177

1 reference

12 August 2017

1 reference